Genitourinary Cancer
From the Journals
Dogs show potential as medical detectives in breast cancer
First preliminary study indicating the feasibility of developing a new breast cancer screening method using urine samples based on volatile...
From the Journals
Overall survival for metastatic urothelial carcinoma approaching 2 years
Metastatic urothelial carcinoma is still a hard-to-treat condition with a 12- to 15-month survival for metastatic disease that is treated. In a...
From the Journals
In and out surgeries become the norm during pandemic
The number of same-day discharges has grown for various surgeries but it’s not always the right or the preferred choice, experts say.
From the Journals
Antibiotic and glucocorticoid use before cancer therapy could have detrimental effect on outcomes
Observational study finds that antibiotics and glucocorticoids at 10 mg daily when given within 1 month before or after immune checkpoint...
Feature
Convenience, not outcomes may drive robot-assisted surgeries
The sale of robotically assisted surgical devices is expected to reach $14 billion by 2028. The technology is enticing to both surgeons and...
From the Journals
Gut bacteria may fuel prostate cancer treatment resistance
The findings may suggest new therapeutic targets: the microbes living in the gut.
From the Journals
Luminal, basal groupings could change metastatic prostate cancer treatment
“These subtypes represent a potentially powerful tool for personalized therapeutic decision-making that may improve outcomes in metastatic mCRPC...
Conference Coverage
Many patients, doctors unaware of advancements in cancer care
“These patients must be spared the traumatic effects of being handed a death sentence that no longer reflects the current reality,” said Dr....
Conference Coverage
Combination treatment shows promise for men with advanced prostate cancer
The combination of nivolumab and rucaparib in a clinical trial showed clinical activity for metastatic prostate cancer cases with BRCA mutations....
Conference Coverage
Most community-based oncologists skip biomarker testing
Survey shows that 48% of community clinicians use biomarker testing to guide treatment decisions, compared with 73% of academic clinicians.
From the Journals
Immunotherapy for cancer patients with poor PS needs a rethink
Patients should not receive immunotherapy just to reduce risk of side effects, doctor says.